- Previous Close
78.07 - Open
78.35 - Bid 77.75 x --
- Ask 77.85 x --
- Day's Range
77.18 - 78.75 - 52 Week Range
62.55 - 119.60 - Volume
23,446 - Avg. Volume
129,643 - Market Cap (intraday)
18.482B - Beta (5Y Monthly) --
- PE Ratio (TTM)
97.31 - EPS (TTM)
0.80 - Earnings Date Mar 6, 2025
- Forward Dividend & Yield 0.15 (0.19%)
- Ex-Dividend Date Apr 25, 2025
- 1y Target Est
--
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
www.galderma.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: GALDZ.XC
View MorePerformance Overview: GALDZ.XC
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GALDZ.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GALDZ.XC
View MoreValuation Measures
Market Cap
18.60B
Enterprise Value
20.49B
Trailing P/E
98.04
Forward P/E
33.33
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.09
Price/Book (mrq)
2.90
Enterprise Value/Revenue
5.62
Enterprise Value/EBITDA
26.03
Financial Highlights
Profitability and Income Statement
Profit Margin
5.20%
Return on Assets (ttm)
3.34%
Return on Equity (ttm)
3.51%
Revenue (ttm)
4.44B
Net Income Avi to Common (ttm)
231M
Diluted EPS (ttm)
0.80
Balance Sheet and Cash Flow
Total Cash (mrq)
457M
Total Debt/Equity (mrq)
35.42%
Levered Free Cash Flow (ttm)
131.38M